Medicines Australia welcomes new AusBiotech CEO
Medicines Australia (MA) congratulates Lorraine Chiroiu on her appointment to CEO of AusBiotech. After eight years with AusBiotech in various roles, most recently as Deputy CEO, Ms Chiroiu is extremely well qualified to lead the organisation in its continuing representation of the life sciences industry.
Interim CEO of MA, Ms Elizabeth de Somer said, “I look forward to working with Lorraine to continue, and strengthen, the collaboration between our organisations. Lorraine will be an excellent voice for the biotechnology industry while her experience means the sector is in good hands.”
MA thanks Mr Glenn Cross, CEO of AusBiotech since 2016, for working constructively and openly with MA on a range of issues impacting both the life sciences and innovative medicines sectors.
Ms de Somer also said, “Under Glenn’s direction, both our organisations have constructively worked in parallel on common issues such as Intellectual Property rights, promoting Australia as a destination for clinical trials, and data protection for biologic medicines. I wish Glenn success with his future.”
|CONTACT: Kim Bessell
Ph. 0423 781 291